CIPROSTENE CALCIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C22H35O4.Ca
Molecular Weight	767.1
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	4
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++].CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@]2(C)C\C(C[C@H]12)=C/CCCC([O-])=O.CCCCC[C@H](O)\C=C\[C@H]3[C@H](O)C[C@]4(C)C\C(C[C@H]34)=C/CCCC([O-])=O

InChI

InChIKey=NJTMVDAFPIEZAJ-BMKVUGPNSA-L

InChI=1S/2C22H36O4.Ca/c2*1-3-4-5-9-17(23)11-12-18-19-13-16(8-6-7-10-21(25)26)14-22(19,2)15-20(18)24;/h2*8,11-12,17-20,23-24H,3-7,9-10,13-15H2,1-2H3,(H,25,26);/q;;+2/p-2/b2*12-11+,16-8-;/t2*17-,18+,19+,20+,22-;/m00./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3068680 | https://www.ncbi.nlm.nih.gov/pubmed/3896365 | https://www.ncbi.nlm.nih.gov/pubmed/1632305

Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostanoid IP receptor 19 Target ID: CHEMBL1995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21129424 \| https://www.ncbi.nlm.nih.gov/pubmed/3005377	Agonist 2752

Patents

Name

Type

Language

U-61,431F

Preferred Name

English

CIPROSTENE CALCIUM

Official Name

English

CALCIUM (Z)-(3AS,5R,6R,6AR)-HEXAHYDRO-5-HYDROXY-6-((E)-(3S)-3-HYDROXY-1-OCTENYL)-3A-METHYL-.DELTA.(SUP 2)(1H),.DELTA.-PENTALENEVALERATE (1:2)

Common Name

English

CIPROSTENE CALCIUM [MART.]

Common Name

English

CIPROSTENE CALCIUM [USAN]

Common Name

English

U-61431F

Code

English

Code System Code Type Description

NCI_THESAURUS

C171867